Posted on

HIGHLIGHTS FROM NEW PUBLISHED RESEARCH ON CBGA AND CBDA

HIGHLIGHTS FROM NEW PUBLISHED RESEARCH ON CBGA AND CBDA

Results from a ground-breaking study published on January 10, 2022 have shown that cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA) block virus–receptor interaction and function as entry inhibitors to prevent infection of human cells by SARS-CoV-2.  

The research focused on determining the binding affinity of CBGA, tetrahydrocannabinolic acid (THCA-A), CBDA, Delta 9-tetrahydrocannabinol, Delta 8-tetrahydrocannabinol, cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), and cannabidiol (CBD) to spike proteins. In the study, potential live SARS-CoV-2 virus cell infection assays were carried out and the two cannabinoids with the highest affinity to bind to the spike protein, CBGA and CBDA were confirmed to block infection of human epithelial cells by a pseudovirus expressing the spike protein. See Table 1, below. The tests showed that both CBDA and CBGA block infection of the original live SARS-CoV-2 virus and variants of concern, including the B.1.1.7 and B.1.351.

Table 1. MagMASS Ranking of Hemp Cannabinoids for Binding to the SARS-CoV-2 Spike Proteina

cannabinoidbUHPLC retention time (min)fold peak area enrichmentc
cannabigerolic acid (CBGA)3.820.5 ± 0.51
tetrahydrocannabinolic acid (THCA-A)8.216.7 ± 2.2
cannabidiolic acid (CBDA)3.712.2 ± 0.52
cannabinolic acid (CBNA)6.55.6 ± 1.4
cannabigerol (CBG)4.13.4 ± 0.82
cannabinol (CBN)5.73.4 ± 0.78
Δ8-tetrahydrocannabinol (Δ8-THC)6.83.1 ± 0.81
Δ9-tetrahydrocannabinol (Δ9-THC)6.83.0 ± 0.77
cannabidiol (CBD)4.22.9 ± 0.72
cannabichromene (CBC)8.12.9 ± 0.75
Cannabidivarin (CBDV)3.01.6 ± 0.17

Reference:

Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants

https://pubs.acs.org/doi/10.1021/acs.jnatprod.1c00946

Richard B. van Breemen*, Ruth N. Muchiri, Timothy A. Bates, Jules B. Weinstein, Hans C. Leier Scotland Farley, and Fikadu G. Tafesse